Clinical trial
A Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP, ATLAS2501 NCCH2413/MK016)
NCT07521670 is registered in ClinicalTrials.gov with National Cancer Centre, Singapore as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP, ATLAS2501 NCCH2413/MK016)
- Lead sponsor
- National Cancer Centre, Singapore
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- October 31, 2028
- Enrollment
- 68 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
adenoid cystic carcinoma metastatic, papillary thyroid carcinoma, recurrent adenoid cystic carcinoma